Method for treating and prognosing cancer like glioblastoma

The present invention relates the treatment and prognostic of cancer like glioblastoma. Here, the inventors focused their study on the impact of presence of N6-adenosine methylation in miRNA-200b-3p in samples of patients suffering from glioblastoma multiforme (GBM). Their study was particularly focused on the impact of miRNA-200b-3p and its adenosine methylation on the expression of XIAP. XIAP acts as an anti-apoptotic protein via the inhibition of caspase-3 and -7 activation and high XIAP expression is associated with a poor survival in several solid tumors. Thus, the miR-200b-3p-mediated repression of XIAP mRNA expression appears as a mechanism governing the caspase-3 and -7 activity and the apoptosis. In theory, in the presence of miR-200b-3p, XIAP mRNA expression is repressed and caspase-3 and -7 can be activated to promote apoptosis. Thus, the present invention relates to an in vitro method for determining the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the miR-200b-3p and/or the N6-adenosine methylated miRNA-200b-3p (miR-200b-3p m6A) in a sample from said patient and to the N6-adenosine methylated miRNA-200b-3p (miR-200b-3p m6A) for use in the treatment of a cancer in a subject in need thereof.

Keywords: miRNA, Glioblastoma, prognosis, miR-200b-3p
Patent Application number: EP20305630.4 on 10/06/2020
PCT/EP2021/065489 on 09/06/2021
Mol Ther Nucleic Acids. 2020 Aug 14;22:72-83. Briand et al. N6-Adenosine Methylation of miRNA-200b-3p Influences Its Functionality and Is a Theranostic Tool doi: 10.1016/j.omtn.2020.08.010.



Business Developper
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2020-06-10

You might also be interested in